Glenmark Pharmaceuticals Ltd Share Price

Pharmaceuticals

NSE: GLENMARK Mid Cap ISIN: INE935A01035

As on 24 April 2025 at 22:48 IST

₹ 1,434.60

+ 22.10

(1.56%)

Sell Buy

Q3 Results:

Glenmark Pharmaceuticals Ltd Q3 Results: Total income for Q3 FY25 rose by 33.98% to ₹34.187 billion, from ₹25.521 billion in the same period last year. Net loss narrowed to ₹3.480 billion from ₹4.496 billion in Q3 FY24.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is a global pharmaceutical company. It operates in the pharmaceutical sector, with a strong presence in respiratory and oncology therapy areas. The company was founded in the year 1977 by Gracias Saldanha and working in the business for decades. The headquarters of the company is located in Mumbai, India. Its main products span various therapeutic areas, including respiratory, dermatology, and oncology. The company is known for its formulations in these segments, which are marketed globally. Some of the company’s notable products include asthma and COPD treatments. +

Over 1 Month

-5.37%

Over 6 Months

-16.22%

Over 1 Year

36.54%

Over 3 Years

230.76%

Glenmark Pharmaceuticals Ltd Summary

Close ₹1,412.50

Open ₹1,400.20

High ₹1,415

Low ₹1,382

Volume 14,62,811

Net Turnover (in Cr) ₹205.41

52Wk High ₹1,830.95

52Wk Low ₹985.20

52Wk High / Low

985.20

1,830.95

Glenmark Pharmaceuticals Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹39,859.08

EPS (TTM) 81.65

Book Value (BV) 848.58

Div. Yield 0.18 %

P/E (TTM) 6.55

Price/Book Value 1.66

Delivery % 61.48 %

Face Value 1

Key Ratios

PE Ratio 5.23

PB Ratio 1.18

EV to Sales 3.50

PEG Ratio 0.02

ROA 21.70

ROE 6.98

Debt-Equity 0.10

Net Profit Margin 18.06

Operating Profit Margin 30.54

Glenmark Pharmaceuticals Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	12,653.09	11,872.14	12,471.58	10,994.15	10,800.57
Total Expenses	11,715.64	10,866.44	10,769.42	9,656.22	9,737.37
Profit Before Tax	36.49	239.84	1,441.25	1,382.47	1,096.08
Profit After Tax	-1,830.85	-89.56	993.65	970.09	775.97
Operating Profit After Depreciation	1,453.42	1,354.73	2,000.26	1,691.04	1,440.52

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	4,452.72	5,545.57	5,976.03	5,292.73	5,159.81
Total Non Current Assets	6,930.54	8,646.15	8,800.94	8,244	7,881.19
Total Current Assets	7,428.08	10,725.53	8,282.35	7,359.58	6,803.62
Total Assets	14,358.62	19,371.68	17,083.29	15,603.58	14,684.81
Total Shareholder's Fund	7,847.93	9,473.92	9,086.65	7,064.63	6,070.51

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash From Operating Activities	-265.44	625.39	1,108.65	1,131.21	1,392.41
Net Cash Used In Investing Activities	4,386.82	-515.44	-315.73	-661.61	-773.75
Net Cash Used In Financing Activities	-3,906.13	-77.46	-520.49	-441.78	-444.66

Profit and Loss

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	9,059.14	9,206.60	8,756.21	7,964.17	7,319.42
Total Expenses	7,128.73	7,138.86	6,849.10	6,094.31	5,803.33
Profit Before Tax	7,000.75	1,571.87	2,337.45	1,943.76	1,534.64
Profit After Tax	5,167.29	1,208.77	1,997.79	1,649.45	1,354.55
Operating Profit After Depreciation	2,207.53	2,274.56	2,143.15	2,135.76	1,772.48

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	1,778.41	1,759.21	1,760.19	1,760.58	1,659.46
Total Non Current Assets	22,732.92	20,199.44	18,511.56	15,708.40	14,527.70
Total Current Assets	4,681.47	4,386.48	4,402.93	4,909.12	4,423.90
Total Assets	27,414.39	24,585.92	22,914.48	20,617.52	18,951.60
Total Shareholder's Fund	22,970.62	17,877.46	16,738.59	14,809.51	13,226.26

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash From Operating Activities	-495.45	1,474.06	1,216.07	1,243.42	1,579.12
Net Cash Used In Investing Activities	3,197.17	-431.52	-897.02	-1,235.19	-1,607.41
Net Cash Used In Financing Activities	-2,666.45	-978.50	-305.12	-80.79	-139.42

Particulars (in ₹ Cr.)	2024-12	2024-09	2024-06	2024-03	2023-12
Total Revenue	3,387.55	3,433.80	3,244.19	3,062.95	2,506.70
Total Expenses	2,787.32	2,831.88	2,655.97	2,558.61	2,715.35
Profit Before Tax	456.33	472.58	462.34	555.20	-402.61
Profit After Tax	348.03	354.49	340.24	-1,214.27	-330.82
Operating Profit after Depreciation	631.36	641.34	619.71	1,301.89	-44.47

Particulars (in ₹ Cr.)	2024-12	2024-09	2024-06	2024-03	2023-12
Total Revenue	2,251.28	2,636.10	2,329.54	2,148.22	1,365.10
Total Expenses	1,757.36	1,857.47	1,698.43	1,650.78	1,549.37
Profit Before Tax	559.49	795.06	618.32	6,294.83	-75.49
Profit After Tax	413.80	595.06	453.73	4,613.70	-20.41
Operating Profit after Depreciation	623.11	861.71	686.76	1,283.71	74.55

Glenmark Pharmaceuticals Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 1,391.33

S2 1,370.17

S3 1,358.33

Pivot 1,403.17

R1 1,424.33

R2 1,436.17

R3 1,457.33

Moving Average

20 SMA 1,448.31

50 SMA 1,418.58

100 SMA 1,471.87

200 SMA 1,534.73

Glenmark Pharmaceuticals Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Glenmark Pharmaceuticals Ltd

₹2.5/Share

Announcement Date 13 Sep 2024

Record Date 17 Sep 2024

Div Yield 250%

Glenmark Pharmaceuticals Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceutical Industries Ltd	₹1,788.90	₹4,29,217.03
Divis Laboratories Ltd	₹5,917.85	₹1,57,100.32
Cipla Ltd	₹1,533.55	₹1,23,852.12
Torrent Pharmaceuticals Ltd	₹3,334.35	₹1,12,844.49
Mankind Pharma Ltd	₹2,545.05	₹1,05,003.30

Glenmark Pharmaceuticals Ltd Top Mutal Funds Invested

Fund Name	AUM
HDFC Mid-Cap Opportunities Fund	1.86%
Mirae Asset Large & Midcap Fund	1.40%
Mirae Asset ELSS Tax Saver Fund	1.64%
Invesco India Contra Fund	1.35%
Mirae Asset Midcap Fund	1.52%

Glenmark Pharmaceuticals Ltd News

Glenmark Pharmaceuticals allots 12,653 equity shares under ESOP

17 Apr 2025, 08:08 pm

Glenmark Pharma's US arm set to launch generic Adderall tablets

Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc., will launch a bioequivalent version of Adderall tablets in strengths ranging from 5 mg to 30 mg, with distribution set to begin in May 2025.

17 Apr 2025, 08:04 am

Glenmark USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets

16 Apr 2025, 07:53 pm

Glenmark Pharmaceuticals Ltd slips for fifth straight session

Glenmark Pharmaceuticals Ltd is quoting at Rs 1371.95, down 0.32% on the day as on 13:19 IST on the NSE. The stock jumped 30.44% in last one year as compared to a 1.61% rally in NIFTY and a 9% spurt in the Nifty Pharma index.

11 Apr 2025, 01:35 pm

Glenmark Pharmaceuticals announces change in senior management

07 Apr 2025, 09:00 am

Glenmark Pharmaceuticals Ltd Stock Analysis

Annual revenue for Glenmark Pharmaceuticals Ltd decreased by 1.60% to ₹9,059.14 crore in FY 2024 from ₹9,206.60 crore in FY 2023.
Annual Net Profit for Glenmark Pharmaceuticals Ltd increased by 327.48% to ₹5,167.29 crore in FY 2024 from ₹1,208.77 crore in FY 2023.
Promoter Shareholding in Glenmark Pharmaceuticals Ltd remains unchanged by 0.00% in the most recent quarter, from 46.65% in December 2024 to 46.65% in March 2025.
Glenmark Pharmaceuticals Ltd delivered a 1-year return of 36.54% compared to the Nifty 50, which provided a return of 8.77% as of the last trading session.
Glenmark Pharmaceuticals Ltd share price moved up by 1.56% from its previous close of INR ₹1,412.50. The latest Glenmark Pharmaceuticals Ltd share price is INR ₹1,434.60.
Glenmark Pharmaceuticals Ltd share price today has been at a low of 1,399 and a high of 1,438.90. Over the past 52 weeks, the Glenmark Pharmaceuticals Ltd share price has seen a low of 985.20 and a high of 1,830.95.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is a global pharmaceutical company. The company's primary focus is to develop and market branded and generic formulations. It operates in the pharmaceutical sector, with a strong presence in respiratory and oncology therapy areas.
Founded by Gracias Saldanha in 1977, Glenmark has been in business for decades. The company is headquartered in Mumbai, India. Its journey began as a generic drug and active pharmaceutical ingredient manufacturer. The company has since evolved into a research-led organisation with a global footprint.
The promoters of Glenmark Pharmaceuticals include the Saldanha family at a 45.45% stake. Glenn Saldanha serves as the Chairman and Managing Director. Under his leadership, the company has expanded its reach and capabilities. To do this, it sets its focus on innovation and advanced therapies. The company also has a team of managerial promoters that includes-

Cherylann Pinto
V S Mani
B E Saldanha
Saira Ramasastry

Glenmark’s main products span various therapeutic areas, including respiratory, dermatology, and oncology. The company is known for its formulations in these segments, which are marketed globally. Some of its notable products include asthma and COPD treatments. It also includes dermatological solutions and oncology drugs.
While Glenmark is a significant player in the pharmaceutical industry, it is not the largest in terms of market share. However, its innovative research and development efforts continue contributing to the sector. The promoter shareholding in Glenmark Pharmaceuticals stands at the top. This indicates a firm commitment from the founding family towards the company’s growth and strategic direction.
The registered office of Glenmark Pharmaceuticals is in Mumbai, Maharashtra. On the other hand, the registrar's office is in the Financial District, Hyderabad. Overall, the company remains a prominent name in the pharmaceutical industry, known for its commitment to research and patient care.

The vision of Glenmark Pharmaceuticals Limited

The company’s vision is centred on improving the quality of life for patients globally. This commitment drives Glenmark to explore new frontiers in medical science. It also helps it to develop therapies that address unmet medical needs. Innovation is at the heart of Glenmark’s vision. The company invests heavily in research and development to discover and create new drugs. This focus on innovation has led to several breakthrough therapies in areas such as oncology and dermatology. Glenmark believes innovation can provide patients with more effective and safer treatment options. Global reach is another key aspect of Glenmark’s vision. The company aims to expand its presence internationally. Through this, it ensures its products are available to patients worldwide. Glenmark operates in over 80 countries, with a strong presence in emerging markets. This global footprint allows the company to reach a diverse patient population and address a wide range of healthcare needs. Sustainability is a crucial part of Glenmark’s vision. The company is committed to conducting its business in an environmentally responsible manner. This includes minimising waste and conserving natural resources. Glenmark believes that sustainable practices are crucial for the planet's long-term health. Patient-centricity is at the core of Glenmark’s vision. The company is committed to understanding the needs and challenges faced by patients. It focuses on developing solutions that enhance their quality of life. The company is committed to understanding the needs and challenges faced by patients. It also focuses on developing solutions that enhance their quality of life. The company collaborates with governments, and non-profit organisations to ensure patients receive the treatments they need. This close cooperation helps improve access to essential healthcare solutions. Collaboration and partnerships play a crucial role in Glenmark’s vision. It believes that working with other organisations can speed up the development of new therapies. This approach aims to bring innovative treatments to market more quickly. Glenmark collaborates with academic institutions and pharmaceutical companies to advance its development efforts. These partnerships enable Glenmark to leverage external expertise and resources, enhancing its innovation ability. Glenmark’s vision extends to its employees as well. The company is committed to fostering a supportive work environment. It focuses on inclusivity, ensuring all employees have the opportunity to thrive. Glenmark invests in the professional development of its workforce. This provides opportunities for learning and growth. The company believes a motivated and skilled workforce is essential for achieving its vision of innovation.
Ethical business practices are a cornerstone of Glenmark’s vision. The company is dedicated to upholding the highest standards of integrity. It ensures transparency in all its operations. This includes adhering to strict regulatory requirements and ensuring the quality and safety of its products. The company also conducts business with honesty and fairness in all its dealings. Glenmark believes that ethical conduct is essential for establishing trust with patients. This commitment extends to all other stakeholders, including healthcare providers and partners.
Looking to the future, Glenmark aims to continue its journey of growth and innovation. The company is focused on expanding its product portfolio to offer a broader range of solutions. Additionally, it aims to enhance its research capabilities to meet evolving market needs. Glenmark’s vision is to be a leading global pharmaceutical company, recognized for its commitment to innovation and patient care.
The company envisions a world where innovative healthcare solutions are accessible to all. Its dedication to these principles guides its efforts to improve the quality and contribute to a healthier future.